Goldman Sachs
RXRX icon

Goldman Sachs’s Recursion Pharmaceuticals RXRX Stock Holding History

Goldman Sachs’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Sell
3,917,858
-2,147,803
-35% -$7.15M ﹤0.01% 2949
2026
Q1 		$18.6M Buy
6,065,661
+3,864,219
+176% +$14.9M ﹤0.01% 2495
2025
Q4 		$9M Buy
2,201,442
+939,822
+74% +$4.65M ﹤0.01% 3195
2025
Q3 		$6.16M Buy
1,261,620
+130,402
+12% +$685K ﹤0.01% 3462
2025
Q2 		$5.72M Sell
1,131,218
-364,645
-24% -$1.79M ﹤0.01% 3288
2025
Q1 		$7.91M Sell
1,495,863
-569,345
-28% -$4.15M ﹤0.01% 2911
2024
Q4 		$14M Buy
2,065,208
+525,504
+34% +$3.53M ﹤0.01% 2468
2024
Q3 		$10.1M Buy
1,539,704
+469,154
+44% +$3.36M ﹤0.01% 2712
2024
Q2 		$8.03M Buy
1,070,550
+173,530
+19% +$1.51M ﹤0.01% 2719
2024
Q1 		$8.94M Sell
897,020
-294,785
-25% -$3.28M ﹤0.01% 2574
2023
Q4 		$11.8M Buy
1,191,805
+527,032
+79% +$3.76M ﹤0.01% 2380
2023
Q3 		$5.09M Buy
664,773
+87,328
+15% +$871K ﹤0.01% 2959
2023
Q2 		$4.31M Buy
577,445
+42,318
+8% +$296K ﹤0.01% 3230
2023
Q1 		$3.57M Sell
535,127
-47,875
-8% -$380K ﹤0.01% 3373
2022
Q4 		$4.49M Buy
583,002
+224,936
+63% +$2.21M ﹤0.01% 3269
2022
Q3 		$3.81M Buy
358,066
+161,999
+83% +$1.64M ﹤0.01% 3384
2022
Q2 		$1.6M Sell
196,067
-13,342
-6% -$89.3K ﹤0.01% 4237
2022
Q1 		$1.5M Buy
209,409
+85,823
+69% +$912K ﹤0.01% 4486
2021
Q4 		$2.12M Buy
123,586
+104,919
+562% +$1.97M ﹤0.01% 4196
2021
Q3 		$429K Buy
18,667
+7,654
+69% +$217K ﹤0.01% 5287
2021
Q2 		$402K Buy
+11,013
New +$326K ﹤0.01% 5343

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's RXRX Position: Q2 2026 in Review

Goldman Sachs reduced its Recursion Pharmaceuticals (RXRX) stake by 35% in Q2 2026, selling an estimated $7.15M and leaving 3,917,858 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Goldman Sachs first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $18.6M in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Goldman Sachs held 3,917,858 shares of Recursion Pharmaceuticals worth $14.4M as of Q2 2026.
  • Goldman Sachs sold 2,147,803 Recursion Pharmaceuticals shares in Q2 2026, an estimated $7.15M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2949 holding.
  • Goldman Sachs first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Goldman Sachs's Recursion Pharmaceuticals position peaked at $18.6M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.